kriyabio


KriyaBio develops and licenses drug delivery technology based on permeation enhancers that reversibly modulate epithelial tight junctions to enable mucosal absorption of APIs otherwise administered by injection. The company focuses on enabling non‑invasive delivery routes (oral, transmucosal, ocular), formulation integration, preclinical development and partnerships to advance early‑stage programs and extend product lifecycles.

Industries

biopharma
biotechnology
delivery
pharmaceutical

Nr. of Employees

small (1-50)

kriyabio


Products

Permeation enhancer platform for mucosal delivery

A platform of permeation enhancers designed to reversibly modulate epithelial tight junctions to increase mucosal absorption of co‑administered APIs, applicable to oral, transmucosal and ocular formulations.


Services

Platform licensing and partnership development

Collaborative licensing and development partnerships to apply the permeation enhancer platform to partner drug candidates and to extend existing product lifecycles.

Formulation and preclinical development services

Development and testing services to integrate permeation enhancers into dosage forms and to generate non‑clinical data supporting clinical translation.

Expertise Areas

  • Mucosal and transmucosal drug delivery
  • Permeation enhancer design and optimization
  • Ocular (transcorneal) delivery for biologics
  • Formulation development for peptides, biologics and low‑permeability small molecules
  • Show More (2)

Key Technologies

  • Tight junction‑modulating permeation enhancers
  • Mucosal delivery platforms (oral, transmucosal)
  • Transcorneal ocular delivery methods
  • Formulation technologies for peptides and biologics
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.